ArticleRadiation oncology (London, England)2019

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.

Makoto Ohno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.